Implantes dentários e bifosfonatos
Amigos ou inimigos?
A presença de osteonecrose dos maxilares tem sido observada em indivíduos que fazem uso de bifosfonatos e foram submetidos a procedimentos cirúrgicos envolvendo dentes e tecido alveolar. O uso de bifosfonatos em combinação com implantes dentários é amplamente utilizado como tratamento na população adulta. O objetivo desta revisão bibliográfica é analisar e sintetizar as evidências científicas de 50 artigos relacionados a casos bem-sucedidos e malsucedidos de colocação de implantes dentários em pacientes tratados com bifosfonatos orais ou intravenosos. Isso é alcançado por meio da busca, seleção e análise dos artigos identificados para identificar padrões, fatores determinantes e lições aprendidas com os casos de sucesso e fracasso relatados na literatura científica. Uma busca bibliográfica foi realizada na base de dados PubMed, que inclui estudos, dados e artigos diretamente relacionados ao tema implantes dentários e bifosfonatos. Dados relevantes foram extraídos dos artigos, como tamanho da amostra, principais resultados e conclusões, e analisados e sintetizados por meio de tabelas comparativas para identificar tendências e diferenças nos efeitos dos bifosfonatos na osseointegração dos implantes e complicações observadas. Em conclusão, a comparação dos 50 artigos sobre implantes dentários e o uso de bifosfonatos revela que essa combinação terapêutica pode apresentar complicações, particularmente osteonecrose dos maxilares. Observou-se que aproximadamente 10% dos pacientes tratados com implantes dentários apresentam complicações que podem levar ao insucesso do tratamento.
Como Citar
Licença
Copyright (c) 2025 Revista Nacional de Odontología
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
O autor deve declarar que seu trabalho é original e inédito e que não foi enviado à avaliação simultânea para sua publicação por outro meio. Além disso, deve garantir que não tem impedimentos de nenhuma natureza para a concessão dos direitos previstos no contrato.
O autor se compromete a esperar o parecer da Revista Nacional de Odontología antes de considerar sua apresentação a outro meio; caso a resposta de publicação seja positiva, compromete-se em responder por qualquer ação de reivindicação, plágio ou outro tipo de reclamação que possa ocorrer por parte de terceiros.
Ainda, deve declarar que, como autor ou coautor, está completamente de acordo com os conteúdos apresentados no trabalho e ceder todos os direitos patrimoniais, isto é, sua reprodução, comunicação pública, distribuição, divulgação, transformação e demais formas de utilização da obra por qualquer meio ou procedimento, pelo termo de sua proteção legal e em todos os países do mundo, ao Fundo Editorial da Universidad Cooperativa de Colombia, de maneira gratuita e sem compensação monetária.
[1] Marx RE. Pamidronate and zoledronate induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1117. DOI: https://doi.org/10.1016/S0278-2391(03)00720-1
[2] Marx RE. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws. History, etiology, prevention, and treatment. Canada: Quintessence Publishing Co, Inc; 2007;150.
[3] Nightingale SL. From the Food and Drug Administration. JAMA, 1995;274:1578. DOI: https://doi.org/10.1001/jama.1995.03530200014013
[4] Berenson JR, Lichtenstein A, Portel L, Dimopoulos MA, et al. Long-term pamidronate treatment of advanced multiple mieloma patients reduces skeletal events. Myeloma Aredia Study Group. Journal Clin Oncol, 1998;16: 593-602. DOI: https://doi.org/10.1200/JCO.1998.16.2.593
[5] Berenson JR, Lichtenstein A, Portel L, Dimopoulos MA, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple mieloma. N. Engl. J. Med, 1996;334:488-493. DOI: https://doi.org/10.1056/NEJM199602223340802
[6] Berenson JR, Rosen LS, Howell A, Porter L, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer, 2001;91:1191-1200. DOI: https://doi.org/10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0
[7] Madrid C, Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Res, 2009;20:87-95. DOI: https://doi.org/10.1111/j.1600-0501.2009.01772.x
[8] Memon S, Weltman RL, Katanncik JA. Oral bisphosphonates: Early endosseous dental implant success and crestal bone changes. A restrospective study. International Journal Oral Maxillofacial Implants, 2012;27:1216-1222.
[9] Benford H, Frith J. Auriola S. Mönkkönen J, Rogers M. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological cases of bis phosphonate drugs. Mol Pharmacol, 1999;56:131-140. DOI: https://doi.org/10.1124/mol.56.1.131
[10] Lynch SE, Buser D, Hernandez RA, Weber HP, et al. Effects of the platelet-derived growth factor/insulin-like growth factor-I combination of bone regeneration around titanium dental implants. Results of a pilot study in Beagle dogs. J. Periodontology, 1991;62(9):710-716. DOI: https://doi.org/10.1902/jop.1991.62.11.710
[11] Sykaras N, Triplett RG, Nunn ME, Iocapino AM, et al. Effect of recombinant human bone morphogenic protein-2 of bone regeneration and osseointegration of dental implants. Clin Oral Implants Res, 2001;12:339-349.
[12] Zechner W, Tangl S, Tepper G, Fürst G, et al. Influence of platelet rich plasma on osseous healing of dental implants: A histologic and histomorphometric study in minipigs. Int J Oral Maxillofac Implants, 2003;18:15-22.
[13] Frenkel S, Jaffe W, Della Valle C, Jazrawi L, et al. The effect of alendronate and implant Surface on bone integration and remodeling in a canine model. J Biomed Mater Res, 2001;58:645-650. DOI: https://doi.org/10.1002/jbm.1064
[14] Jakobsen T, Kold S, Bechtold B, Elmengaard B, et al. Local alendronate increases fixation of implants inserted with bone compaction: 12-week canine study. J Orthop Res, 2007;25:432-441. DOI: https://doi.org/10.1002/jor.20276
[15] Jensen T, Bechtold J, Chen X, Soballe K. Systemic alendronate treatment improves fixation of press-fit implants: A canine study using nonloaded implants. J Orthop Res, 2007;25:772-778. DOI: https://doi.org/10.1002/jor.20272
[16] Tengvall P, Skoglund B, Askendal A, Aspenberd P. Surface immobilized bisphosphonate improves stainless-steel screw fixation in rats. Biomaterials, 2004;469:514-522. DOI: https://doi.org/10.1016/j.biomaterials.2003.08.049
[17] McKenzie K, Dennis J, Roberts J, Karabasz D, et al. Bisphosphonate remains highly localized after elution from porous implants. Clin Orthop Relat Res, 2011;42:365-371. DOI: https://doi.org/10.1007/s11999-010-1527-x
[18] Wermelin K, Suska F, Tengvall P, Thomsen P, et al. Stainless Steel screws coated with bisphosphonates gave stronger fixation and more surrounding bone. Histomorphometry in rats. Bone, 2008;42:1228-1233. DOI: https://doi.org/10.1016/j.bone.2007.12.065
[19] Meraw SJ, Reeve CM. Qualitative análisis of peripheral peri-implant bone and influence of alendronate sodium on early bone regeneration. J Periodontol, 1999;70:1228-1233. DOI: https://doi.org/10.1902/jop.1999.70.10.1228
[20] Ganguli A, Henderson C, Grant MH, Meikle ST, et al. The interactions of biphosphonates in solution and as coating on hydroxyapatyte. J MaterSci Mater Med, 2002;13:923-931. DOI: https://doi.org/10.1023/A:1019892109411
[21] Goss A, Bartold M, Sambrook P, Hawker P. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: A south australian case series. J Oral Maxillof Surg. 2010;68(2):337-343. DOI: https://doi.org/10.1016/j.joms.2009.09.037
[22] Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American association of oral and maxillofacial surgeons position paper on bisphosphonate related osteonecrosis of the jaws. J Oral Maxillof Surg. 2007;65(3):369-376. DOI: https://doi.org/10.1016/j.joms.2006.11.003
[23] Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. Journal of Dental Research. 2007;86(11):1013-1021. DOI: https://doi.org/10.1177/154405910708601101
[24] Cavanna L, Bertè R, Arcari A, Mordenti P, Pagani R, Vallisa D. Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature. European Journal of Internal Medicine. 2007;18(5):417-422. DOI: https://doi.org/10.1016/j.ejim.2006.10.008
[25] Siddiqi A, Payne AG, Zafar S. Bisphosphonate-induced osteonecrosis of the jaw: A medical enigma?. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology. 2009;108(3):e1-e8. DOI: https://doi.org/10.1016/j.tripleo.2009.04.027
[26] Ruggiero SL, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. Journal of Oncology Practice. 2006;2(1):7-14. DOI: https://doi.org/10.1200/jop.2006.2.1.7
[27] Lee CY, Suzuki JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonateassociated osteonecrosis of the jaws after surgery? Part II: A prospective clinical study. Implant Dentistry. 2010;19(1):29-38. DOI: https://doi.org/10.1097/ID.0b013e3181cec8bc
[28] Don-Wauchope AC, Cole DE. The (mis) use of bone resorption markers in the context of bisphosphonate exposure, dental surgery and osteonecrosis of the jaw. Clinical Biochemistry. 2009;42(10-11):1194-1196. DOI: https://doi.org/10.1016/j.clinbiochem.2009.02.014
[29] Bedogni A, Bettini G, Totola A, Saia G, Nocini PF. Oral bisphosphonate–associated osteonecrosis of the jaw after implant surgery: A case report and literature review. Journal of Oral and Maxillofacial Surgery. 2010;68(7):1662-1666. DOI: https://doi.org/10.1016/j.joms.2010.02.037
[30] Fleisch H, Russell RG, Bisaz S, Mühlbauer R. Influence of diphosphonates on the deposition and dissolution of calcium phosphate in vitro and in vivo. Helv Physiol Pharmacol Acta.1968;26:CR345–6.
[31] Francis MD, Russell RG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 1969;165:1264–6. DOI: https://doi.org/10.1126/science.165.3899.1264
[32] Mínguez MP, Llorca CS, Silvestre FJ. Oral implants in patients receiving bisphosphonates: A review and update. Medicina Oral, Patología Oral y Cirugía Bucal. 2008;13(12):E755-E760.
[33] Effect of recombinant human bone morphogenic protein-2 of bone regeneration and osseointegration of dental implants. Clin Oral Implants Res. 2001;12:339–49. DOI: https://doi.org/10.1034/j.1600-0501.2001.012004339.x
[34] Toksvig-Larsen S, Aspenberg P. Bisphosphonate-coated external fixation pins appear similar to hydroxyapatite-coated pins in the tibial metaphysis and to uncoated pins in the shaft. Acta Orthop. 2013;84:314–8. DOI: https://doi.org/10.3109/17453674.2013.797315
[35] Prieto-Alhambra D, Javaid MK, Judge A, Murray D, Carr A, Cooper C. Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: Population based retrospective cohort study. BMJ. 2011;343:d7222. DOI: https://doi.org/10.1136/bmj.d7222
[36] Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A register-based national cohort study. J Bone Miner Res. 2009;24:1095–1102. DOI: https://doi.org/10.1359/jbmr.081247
[37] Nieves JW, Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep. 2010;8:34–39. DOI: https://doi.org/10.1007/s11914-010-0007-2
[38] Abtahi J, Agholme F, Sandberg O, Aspenberg P. Effect of local vs systemic biphosphonate delivery on dental implant fixation in a model of osteonecrosis of the jaw. J Dent Res. 2013;92:279–83. DOI: https://doi.org/10.1177/0022034512472335
[39] Bobyn JD, Hacking SA, Krygier JJ, Harvey EJ, Little DG, Tanzer M. Zoledronic acid causes enhancement of bone growth into porous implants. J Bone Joint Surg. 2005;87:416–20. DOI: https://doi.org/10.1302/0301-620X.87B3.14665
[40] Von Knoch M, Wedemeyer C, Pingsmann A. The decrease of particle-induced osteolysis after a single dose of bisphosphonate. Biomaterials. 2005;26:1803–8. DOI: https://doi.org/10.1016/j.biomaterials.2004.06.010
[41] Peter B, Pioletti DP, Laib S. Calcium phosphate drug delivery system: Influence of local zoledronate release on bone implant osteointegration. Bone. 2005;36:52–60. DOI: https://doi.org/10.1016/j.bone.2004.10.004
[42] Wise LM, Waldman SD, Kasra M. Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog. Calcif Tissue Int. 2005;77:367–75. DOI: https://doi.org/10.1007/s00223-005-0062-3
[43] Abtahi J, Tengvall P, Aspenberg P. A bisphosphonate-coating improves the fixation of metal implants in human bone. A randomized trial of dental implants. Bone. 2012;50:1148–51. DOI: https://doi.org/10.1016/j.bone.2012.02.001
[44] Koka S, Babu NM, Norell A. Survival of dental implants in post-menopausal biphosphonate users. J Prosthodont Res. 2010;54:208–11. DOI: https://doi.org/10.1016/j.jpor.2010.04.002
[45] Tsetsenekou E, Papadopoulos T, Kalyvas D, Papaioannou N, Tangl S, Watzek G. The influence of alendronate on osseointegration of nanotreated dental implants in New Zealand rabbits. Clin Oral Implants Res. 2012;23:659–66. DOI: https://doi.org/10.1111/j.1600-0501.2011.02189.x
[46] Kasai T, Pogrel MA, Hossaini M. The prognosis for dental implants placed in patients taking oral bisphosphonates. J Calif Dent Assoc. 2009;37:39–42. DOI: https://doi.org/10.1080/19424396.2009.12222946
[47] Lazarovici TS, Yahalom R, Taicher S, Schwartz-Arad D, Peleg O, Yarom N. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg. 2010;68:790–6. DOI: https://doi.org/10.1016/j.joms.2009.09.017
[48] Qi M, Hu J, Li J, Li J, Dong W, Feng X. Effect of zoledronate acid treatment on osseointegration and fixation of implants in autologous iliac bone grafts in ovariectomized rabbits. Bone. 2012;50:119–27. DOI: https://doi.org/10.1016/j.bone.2011.10.011
[49] Bell BM, Bell RE. Oral bisphosphonates and dental implants: A retrospective study. J Oral Maxillofac Surg. 2008;66:1022–4. DOI: https://doi.org/10.1016/j.joms.2007.12.040
[50] Stark WJ, Epker BN. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: A case report. Int J Oral Maxillofac Implants. 1995;10:74–8.
